Clinical trial · Interventional
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors
NCT00080041CI-TRIAL-00000728completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Motexafin Gadolinium Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Determine the Dose Limiting Toxicity at 3 weeks (1 cycle), and the Maximum Tolerated Dose at 24 weeks (6 cycles).
Secondary outcomes (1)
- measure
- Frequency of tumor responses at weeks 6, 12 and 18.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years old * Histologically or cytologically confirmed diagnosis of cancer (i.e., Unresectable locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) that had progressed during or after one or more chemotherapy regimens; Metastatic breast cancer; Hormone-refractory prostate cancer; Recurrent or refractory ovarian cancer; Sarcoma) * ECOG performance status score either 0 or 1 * Willing and able to provide written informed consent Exclusion Criteria: Laboratory Values of: * Absolute neutrophil count \< 2000/µL * Platelet count \< 100,00/µL * AST or ALT \> 1.5 x the upper limit of normal * Alkaline phosphatase \> 5 x the upper limit of normal * Bilirubin \> ULN * Creatinine \> 2.0 mg/dL and * Peripheral neuropathy NCI CTC Grade 3 or higher * Chemotherapy, radiation therapy, immunotherapy, or systemic biologic * anticancer therapy within 21 days before beginning study treatment * Known history of brain metastases or spinal cord compression * Uncontrolled hypertension * Myocardial infarction within 6 months before beginning study treatment * Unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled serious arrhythmias * Known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80 * Known history of porphyria (testing not required at screening) * Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening) * Known history of HIV infection (testing not required at screening) * Female who is pregnant or lactating (pregnancy test is required for all female patients of childbearing potential) * Female of childbearing potential or sexually active male unwilling to use adequate contraceptive protection * Physical or mental condition that makes patient unable to complete specified follow-up assessments
References
Publications (0)
Data not yet available
No reference posted for this study.